Ascendis Pharma A/S
ascendispharma.dkWhat Do They Do?
Develops and sells TransCon-based medicines for people with endocrine rare diseases, and develops partnered therapies for other disease areas.
20-F for FY2025, filed Feb 11, 2026We are a global biopharmaceutical company focused on applying our innovative TransCon technology platform to make a meaningful difference…View ↗
We currently have two marketed products and a diversified portfolio consisting of four product candidates in clinical development in the…View ↗
YORVIPATH® (palopegteriparatide), was developed as TransCon PTH and was approved by the U.S. Food & Drug Administration (“FDA”), and…View ↗
SKYTROFA® (lonapegsomatropin-tcgd) was developed as TransCon hGH and approved by the FDA for the treatment of pediatric patients one year…View ↗
Endocrinology Rare Disease Pipeline – Two product candidates in our Endocrinology Rare Disease portfolio are currently in development for…View ↗
Who Are Their Customers?
Healthcare providers prescribe its medicines, while specialty pharmacies distribute them in the United States. In Europe, the company sells directly in selected countries and uses sales and distribution partners in other markets; collaborations and license agreements also involve customers.
20-F for FY2025, filed Feb 11, 2026YORVIPATH® (palopegteriparatide), was developed as TransCon PTH and was approved by the U.S. Food & Drug Administration (“FDA”), and…View ↗
In the U.S., we have established an integrated organization to commercialize our approved Endocrinology Rare Disease products, YORVIPATH…View ↗
In Europe, we have established our presence by building integrated organizations to commercialize our approved Endocrinology Rare Disease…View ↗
Beyond the U.S. and Europe Direct, we are expanding global reach for our Endocrinology Rare Disease products through exclusive sales and…View ↗
Other revenue relates to collaboration and license agreements (or “Strategic Collaborations”), where the counterparts are considered…View ↗
How Are They Changing?
More medicines on the market
The company has moved from one marketed medicine to two, while continuing to develop candidates in endocrinology rare diseases and oncology.
20-F for FY2022, filed Feb 16, 2023 20-F for FY2025, filed Feb 11, 2026We currently have one marketed product and a diversified portfolio of five product candidates in clinical development in the areas of…View ↗
We currently have two marketed products and a diversified portfolio consisting of four product candidates in clinical development in the…View ↗
Broader commercial reach
The earlier report described building a commercial presence in North America and selected European countries through partners. The latest report describes integrated sales in the United States and selected European countries, with agreements covering additional international markets.
20-F for FY2022, filed Feb 16, 2023 20-F for FY2025, filed Feb 11, 2026In the U.S., we have established an integrated organization to commercialize our approved Endocrinology Rare Disease products, YORVIPATH…View ↗
In Europe, we have established our presence by building integrated organizations to commercialize our approved Endocrinology Rare Disease…View ↗
Beyond the U.S. and Europe Direct, we are expanding global reach for our Endocrinology Rare Disease products through exclusive sales and…View ↗
Who Do They Compete With?
Competes with Extend Biosciences, Nektar Therapeutics, OPKO Health, ProLynx, MBX Biosciences, and Serina Therapeutics
20-F for FY2025, filed Feb 11, 2026We are aware that other companies are developing or evaluating enhanced drug delivery and sustained release technologies, which may be…View ↗
Loading...
